Why the Vonoprazan Helicobacter pylori Therapies in the US-European Trial Produced Unacceptable Cure Rates
- 1 March 2023
- journal article
- review article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 68 (5) , 1691-1697
Abstract
Introduction Helicobacter pylori infects a large percentage of the world’s population and is etiologically related to gastric cancer. The U.S. Food and Drug Administration recently approved two 14-day vonoprazan-containing regimens (vonoprazan–amoxicillin with or without clarithromycin) for H. pylori infections in the United States/Europe. Methods We critically reviewed the trial methods to discover why the results were unacceptable low [i.e., no regimen achieved clinically acceptable (≥ 90%) or even conditionally acceptable cure rates (≥ 85%)]. Cure rates with antibiotic susceptible strains were 84.7 for vonoprazan triple therapy, 78.5 for vonoprazan–amoxicillin, and 78.7 for lansoprazole triple therapy, respectively. As was previously shown in Japan, the benefit from adding clarithromycin to vonoprazan–amoxicillin was minimal and the majority of the clarithromycin administered was unnecessary. Results The possible reasons for failure to achieve high cure rates discussed include (a) reduced intragastric antibiotic concentrations, (b) an increase in heteroresistance, and (c) failure to achieve an intragastric pH conducive for amoxicillin to eradicate the infection. In addition, there was no pilot study or other attempt to optimize any regimen. Conclusion The most likely reason for failure was failure to achieve high intragastric concentrations of antibiotics or to achieve an intragastric pH conducive for amoxicillin to be active. Importantly, vonoprazan triple therapy resulted in > 10 tons of unneeded clarithromycin/million courses of vonoprazan triple therapy. Antibiotic misuse combined with low cure rates suggest that vonoprazan–clarithromycin triple therapies should not be prescribed for H. pylori infection. Dual vonoprazan–amoxicillin therapy has proven effective elsewhere and after optimization may eventually prove useful in the U.S./Europe.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (DK56338)
This publication has 30 references indexed in Scilit:
- Vonoprazan Helicobacter pylori eradication therapy: ethical and interpretation issuesGut, 2016
- Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind studyGut, 2016
- Hp‐normogram (normo‐graham) for Assessing the Outcome of H. pylori Therapy: Effect of Resistance, Duration, and CYP2C19 GenotypeHelicobacter, 2015
- Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese SubjectsClinical and Translational Gastroenterology, 2015
- Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK‐438 (vonoprazan), a novel potassium‐competitive acid blocker, in healthy male subjectsAlimentary Pharmacology & Therapeutics, 2015
- High-dose versus standard-dose PPI in triple therapy for Helicobacter pylori eradicationNature Reviews Gastroenterology & Hepatology, 2009
- Comparison of an increased dosage regimen of rabeprazole versus a concomitant dosage regimen of famotidine with rabeprazole for nocturnal gastric acid inhibition in relation to cytochrome P450 2C19 genotypesClinical Pharmacology & Therapeutics, 2005
- Current FDA-Approved Treatments for Helicobacter pylori and the FDA Approval ProcessGastroenterology, 1997
- An endoscopic topical therapy for the treatment of Helicobacter pylori infectionGastroenterology, 1995
- What Happens to Tablets and Capsules in the Stomach: Endoscopic Comparison of Disintegration and Dispersion Characteristics of Two Microencapsulated Potassium FormulationsJournal of Pharmaceutical Sciences, 1990